Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B7-H1 Antigen | 3 | 2023 | 129 | 1.660 |
Why?
|
| Tumor Microenvironment | 5 | 2024 | 698 | 1.540 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 652 | 1.420 |
Why?
|
| Cancer Vaccines | 8 | 2020 | 190 | 1.200 |
Why?
|
| Mice, Inbred BALB C | 15 | 2023 | 1089 | 1.060 |
Why?
|
| Receptor, ErbB-2 | 7 | 2020 | 559 | 1.020 |
Why?
|
| B7 Antigens | 1 | 2024 | 14 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1356 | 0.870 |
Why?
|
| CD47 Antigen | 1 | 2023 | 11 | 0.810 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 68 | 0.800 |
Why?
|
| Liposomes | 10 | 2020 | 207 | 0.780 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 145 | 0.760 |
Why?
|
| Cell Line, Tumor | 13 | 2024 | 3798 | 0.700 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 1853 | 0.690 |
Why?
|
| Radiobiology | 1 | 2020 | 3 | 0.680 |
Why?
|
| Cytokines | 5 | 2024 | 1401 | 0.680 |
Why?
|
| Melanoma, Experimental | 1 | 2020 | 38 | 0.680 |
Why?
|
| Infectious hematopoietic necrosis virus | 1 | 2019 | 1 | 0.640 |
Why?
|
| Rhabdoviridae Infections | 1 | 2019 | 4 | 0.640 |
Why?
|
| Fish Diseases | 1 | 2019 | 11 | 0.640 |
Why?
|
| Epitopes | 2 | 2021 | 446 | 0.620 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2019 | 130 | 0.620 |
Why?
|
| Epidemics | 1 | 2019 | 59 | 0.600 |
Why?
|
| Selection, Genetic | 1 | 2019 | 169 | 0.590 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1622 | 0.590 |
Why?
|
| Neoplasms | 4 | 2024 | 3038 | 0.580 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2019 | 246 | 0.580 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 137 | 0.570 |
Why?
|
| Melanoma | 1 | 2024 | 967 | 0.540 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 907 | 0.530 |
Why?
|
| HLA-DR Antigens | 1 | 2017 | 80 | 0.530 |
Why?
|
| Fas Ligand Protein | 1 | 2016 | 38 | 0.510 |
Why?
|
| fas Receptor | 1 | 2016 | 50 | 0.510 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 710 | 0.480 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1812 | 0.480 |
Why?
|
| CpG Islands | 1 | 2017 | 347 | 0.480 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 70 | 0.480 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2020 | 521 | 0.450 |
Why?
|
| Animals | 22 | 2023 | 36557 | 0.430 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 227 | 0.430 |
Why?
|
| Apoptosis | 3 | 2024 | 1946 | 0.390 |
Why?
|
| Peptide Fragments | 5 | 2020 | 834 | 0.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 507 | 0.390 |
Why?
|
| Peptides | 4 | 2020 | 863 | 0.390 |
Why?
|
| Tumor Burden | 5 | 2020 | 259 | 0.380 |
Why?
|
| Mice | 14 | 2023 | 19055 | 0.380 |
Why?
|
| Ligands | 2 | 2024 | 572 | 0.370 |
Why?
|
| Bacterial Vaccines | 2 | 2021 | 103 | 0.340 |
Why?
|
| Bacterial Outer Membrane Proteins | 2 | 2021 | 117 | 0.330 |
Why?
|
| Acinetobacter baumannii | 2 | 2021 | 47 | 0.330 |
Why?
|
| Spleen | 3 | 2019 | 292 | 0.280 |
Why?
|
| Interferon-gamma | 5 | 2020 | 538 | 0.250 |
Why?
|
| Nanoparticles | 5 | 2020 | 290 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 3 | 2016 | 392 | 0.230 |
Why?
|
| Female | 18 | 2023 | 71928 | 0.220 |
Why?
|
| Acinetobacter Infections | 2 | 2021 | 36 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1072 | 0.210 |
Why?
|
| Immunotherapy | 4 | 2024 | 752 | 0.210 |
Why?
|
| Gene Silencing | 1 | 2024 | 247 | 0.210 |
Why?
|
| Computer Simulation | 2 | 2024 | 707 | 0.210 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 272 | 0.210 |
Why?
|
| Organoplatinum Compounds | 1 | 2023 | 34 | 0.200 |
Why?
|
| Leucovorin | 1 | 2023 | 54 | 0.200 |
Why?
|
| Immunity | 3 | 2020 | 187 | 0.200 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 63 | 0.200 |
Why?
|
| Fluorouracil | 1 | 2023 | 141 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 452 | 0.200 |
Why?
|
| Hypoxia | 1 | 2024 | 268 | 0.190 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 257 | 0.180 |
Why?
|
| Antigens, Bacterial | 2 | 2021 | 320 | 0.180 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 232 | 0.170 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 81 | 0.170 |
Why?
|
| Cell Movement | 1 | 2024 | 920 | 0.170 |
Why?
|
| Relative Biological Effectiveness | 1 | 2020 | 8 | 0.170 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 2771 | 0.170 |
Why?
|
| Oncorhynchus mykiss | 1 | 2019 | 2 | 0.160 |
Why?
|
| Aquaculture | 1 | 2019 | 9 | 0.160 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2019 | 34 | 0.160 |
Why?
|
| Iran | 1 | 2019 | 93 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 253 | 0.160 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 400 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2020 | 303 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 128 | 0.150 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 162 | 0.150 |
Why?
|
| Protein Unfolding | 1 | 2018 | 13 | 0.150 |
Why?
|
| Drug Synergism | 1 | 2019 | 242 | 0.150 |
Why?
|
| Lactococcus lactis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Sublingual Immunotherapy | 1 | 2018 | 5 | 0.150 |
Why?
|
| Nanostructures | 2 | 2016 | 65 | 0.150 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2016 | 35 | 0.140 |
Why?
|
| Antigens, Plant | 1 | 2018 | 42 | 0.140 |
Why?
|
| Gold | 1 | 2018 | 57 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 247 | 0.140 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2016 | 50 | 0.140 |
Why?
|
| Metal Nanoparticles | 1 | 2018 | 59 | 0.140 |
Why?
|
| Disease Progression | 1 | 2024 | 2266 | 0.140 |
Why?
|
| Fibrinogen | 1 | 2018 | 163 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 462 | 0.130 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2563 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2019 | 399 | 0.130 |
Why?
|
| Protein Corona | 1 | 2016 | 2 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 519 | 0.130 |
Why?
|
| Immunization | 4 | 2021 | 315 | 0.130 |
Why?
|
| Poly I-C | 1 | 2016 | 26 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1310 | 0.130 |
Why?
|
| Leishmania major | 1 | 2016 | 27 | 0.130 |
Why?
|
| Phospholipids | 1 | 2017 | 114 | 0.130 |
Why?
|
| Neuraminidase | 1 | 2016 | 39 | 0.120 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2016 | 48 | 0.120 |
Why?
|
| Allergens | 1 | 2018 | 278 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2018 | 194 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4808 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4879 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 224 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2019 | 1599 | 0.120 |
Why?
|
| Cell Line | 2 | 2017 | 2864 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 867 | 0.110 |
Why?
|
| Lipid A | 1 | 2014 | 24 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2016 | 191 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2015 | 148 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 2198 | 0.110 |
Why?
|
| Dendritic Cells | 1 | 2017 | 449 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2014 | 139 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2021 | 951 | 0.110 |
Why?
|
| Humans | 10 | 2024 | 134156 | 0.090 |
Why?
|
| Genotype | 1 | 2016 | 2814 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2017 | 276 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3506 | 0.060 |
Why?
|
| Pregnancy | 1 | 2016 | 7570 | 0.050 |
Why?
|
| Young Adult | 1 | 2016 | 9944 | 0.050 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2020 | 51 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 266 | 0.040 |
Why?
|
| Salsola | 1 | 2018 | 1 | 0.040 |
Why?
|
| Surface Properties | 1 | 2018 | 96 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2018 | 117 | 0.030 |
Why?
|
| Adolescent | 1 | 2016 | 20624 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2017 | 51 | 0.030 |
Why?
|
| Fluorescence | 1 | 2017 | 102 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2018 | 190 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 180 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2017 | 321 | 0.030 |
Why?
|
| Transition Temperature | 1 | 2017 | 4 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 390 | 0.030 |
Why?
|
| Transgenes | 1 | 2018 | 346 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 31 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2016 | 26 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2018 | 873 | 0.030 |
Why?
|
| Psychodidae | 1 | 2016 | 15 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 399 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 720 | 0.030 |
Why?
|
| Drug Stability | 1 | 2015 | 62 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2015 | 36 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 451 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 153 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 2795 | 0.030 |
Why?
|
| Adult | 1 | 2016 | 31945 | 0.030 |
Why?
|
| Base Sequence | 1 | 2019 | 3180 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 890 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 56 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 132 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2014 | 105 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 214 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3188 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 5086 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 566 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 1595 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4598 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 13074 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 6610 | 0.010 |
Why?
|